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Abstract 
Cancer which is also referred to as malignant neoplasm is a group of diseases involving 
abnormal cell growthwith the capacity to invade and spread throughout the body. The most 
frequently diagnosed cancer has been found to be breast cancer and it is also the leading 
cause of death by cancer among females, accounting for 23% of the total cancer cases and 
14% of the cancer deaths. The ongoing discovery of newer cancer as a result of mutations has 
been a driving force in the design, synthesis and development of newer chemo-therapeutic 
agents which combat cancer.  As a contribution to these efforts, we synthesized compounds 
specifically targeting cancerous cells. A series of eleven 2 quinolone-urea/thiourea hybrid 
molecules were synthesized by a simple Pachman condensation reaction followed by the 
reaction of the newly synthesized 2-quinolone with various substituted isocynates and 
isothiocyantes leading to the lead compounds which were evaluated for their activity 
potential against TB H37Rv strain and bacterial clinical strains. Pass online tool (Prediction of 
activity spectra for substances) was also used to predict the activity potential of these 
compounds and the reflected high probability of these compounds to be used as anticancer 
agents. The compounds also reflected low to moderate activity of these compounds as 
antimicrobial agents as well as antitubercular agents which. The PASS results were 
confirmed by our experimental work. The synthesized compounds were confirmed by 




C-NMR spectroscopy. The yield of these compounds 
obtained ranged from 40% to 80%.  The synthesized compounds displayed moderate activity 
towards E.coli ATCC35218 and S.pneuminiae ATCC49619 strains with highest MIC of 
12.5µg/mL respectively. PASS activity prediction also showed good Pa (probability to be 
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1.1 BACKGROUND AND RATIONAL OF THIS STUDY 
The work in this thesis is an effort towards understanding the 2-quinolone moiety in drug 
discovery and its anticancer activity and additionally its antitubercular and antimicrobial 
activities. Cancer which is also referred to as malignant neoplasm is a disease which can 
affect any part of the body and it is characterized by cell growth which is unregulated and out 
of control
1,2
. There are many different types of cancers which affect different parts of the 
body such as breasts, prostrate, lymph glands, bone marrow etc
3
. Cancer becomes harmful to 
the body when cells continue to divide uncontrollably and form tumours. Tumours have the 
ability to grow and further divide and consequently affect body systems such as the 
circulatory, digestive and nervous systems and they can also discharge hormones that alter 
normal body functions
4
. Benign tumours are localised in a specific part of the body and 
demonstrate limited growth
5
. Many drugs have been designed and used to combat cancer. 
These drugs were designed with intent to target specific sites within the cancerous cell or 
mechanisms which are responsible for causing cancer when unregulated. There are various 
drug targets including telomerase, topoisomerase and NF-κB in which many synthesized 
drugs act
6,7
. The drugs which act on these target sites are effective and have been used to treat 
various cancers. However, due to mutations and the emergence of different environmental 
factors have made it difficult to treat cancer and the current drugs are quickly becoming less 
significant in the treatments of cancers. Hence, there is a great need to develop new 




Quinolones are a family of synthetic broad-spectrum antibacterial agents which exert their 
antibacterial effect by preventing bacterial DNA from unwinding and duplicating. Some 
quinolones selectively inhibit the topoisomerase II ligase domain
9,10
. This modification on the 
topoisomerase II ligase domain leads to DNA disintegration via the nuclease activity of the 
intact enzyme domains
11,12
. Some quinolone analogues have been enhanced to be more 
selective for topoisomerase IV ligase domain, and this has given them improvedGram- 
positive coverage
13
. The protein target of quinolones in many Gram-negative bacteria is DNA 
gyrase and topoisomerase IV for many Gram-positive bacteria
14
. Some derivatives of 
quinolones display high activity not only against bacterial topoisomerases, but also against 
eukaryotic topoisomerases which are toxic to cultured mammalian cells and in vivo tumour 
models
15
. Therefore these cytotoxic classes of quinolone derivatives indicate an exploitable 
source of new anticancer agents. The quinolone pharmacophore has also been found to inhibit 




NF-κB which is a protein complex that controls transcription of DNA. Incorrect regulation of 
NF-κB has been linked to cancer, inflammatory, autoimmune diseases, septic shock, viral 
infection and improper immune development
16,17
.  
Therefore with the above evidences in mind, this thesis is directed at investigating the 
anticancer potential of the 2-quinolone pharmacophore and its novel derivatives. The novel 
compounds will also be subjected to in vitro screening against tuberculosis (H37Rv strain) 
and bacterial clinical isolates to further evaluate their pharmacological activity. 
 
 
1.1 AIMS OF THIS STUDY 
1.2.1 To synthesize 7-amino-4-methyl-2-quinolone urea/ thiourea derivatives 
1.2.2 To evaluatethe synthesised compounds against a panel of cancer cell lines 
1.2.3 To further screen the synthesized compounds against Mycobacterium 
 tuberculosis and Gram-positive and Gram-negative bacterial clinical isolates. 
1.3 OBJECTIVES OF THIS STUDY 
1.3.1 To synthesize 7-amino-4-methyl-2-quinolone urea/ thiourea derivatives by a 
 reaction between an intermediate 7-amino-4-methyl-2-quinolone with 
 different isocyanates and isothiocyanates.  
1.3.2 To carry out anticancer evaluation using MTT assay against eleven cancer cell 
 lines (MCF7, CaCO2, K-562, ECV-304, UACC-257, PC-3, WRL68, PA1, 
 TK-10, HOP-62, andKB403) 
1.3.3 To carry out antitubercular testing against H37Rv strain. 
1.3.4 To carry out antimicrobial screening against a panel of Gram-positive as well 
 as Gram-negative bacteria employing the minimal inhibitory concentration 
 (MIC) technique. 
 
1.4 NOVELTY AND SIGNIFICANCE OF THIS STUDY 
Previous studies on the 2-quinolone ring reported the synthesis of this pharmacophore 
coupled with amino acids, thiazolidinones, thiazoles, mannich bases etc. However, no 
investigations have been reported to date on the reaction of 7-amino-4-methyl-2-quinolone 
with isocyanates and isothiocyanates to yield quinolone urea/thiourea derivatives. The current 




study is the first of its kind and the findings of these hybrid molecules are reported in this 
thesis. Another important aspect, which highlights the novelty of this work, is evaluating 2-
quinolone and its derivatives as potential anticancer agents. Further no study has been 
reported on urea coupled to the amino group at C-7 of the 2-quinolone ring as evidenced by 
literature search till date. The work presented will contribute further towards understanding 
of anticancer properties. Also, this study could serve as a road map for further target-based 
anticancer drug design and development. 
1.5 OVERVIEW OF THIS THESIS 
This thesis is divided into 5 chapters, including its overview. 
Chapter 1: This chapter addresses the background, aim and objectives, significance as well 
as the general outline and structure of the thesis. 
Chapter 2: It provides a general overview on cancer, cancer drugs and their target sites as 
well as brief account on current marketed drugs for cancer chemotherapy. The chapter starts 
with a historic background of cancer followed by the pathophysiology of cancer and the 
different mechanisms of cancer formation including some updated statistics. The chapter also 
highlights many aspects of quinolone scaffold and its wide range of pharmacological 
activities, chemistry and quinolones coupled to other pharmacophores. The topoisomerase 
enzyme and NF-κB enzyme are crucial drug targets and the main focus of the work towards 
anticancer evaluation. Secondly the DNA gyrase and tuberculosis H37Rv strain are also 
mentioned as drug targets for the synthesized novel compounds.  
Chapter 3: This chapter provides experimental data, description of different spectroscopic 
techniques employed to confirm the formation of the desired novel target compounds and 
their schematic representation. The chapter also displays concise synthetic strategy and 
mechanisms of the entire reaction leading to the formation of the novel compounds. 
Procedures or assay methods employed to evaluate the biological activity have also been 
explained in this chapter. 
Chapter 4: This chapter highlights the results obtained during the course of the research and 
their discussion. Physico-chemical properties of the synthesized derivatives such as purity, 
appearance, molecular weight and percentage yield observed have been reported. The chapter 
also focuses on spectroscopic characterization data to verify the formation of the compounds 
and lists some examples of spectrums obtained with respect to synthesized compounds. 




Chapter 5: This chapter focuses on general concluding remarks and future scope of the 
research work which includes different possibilities on chemical modifications of the 2- 
quinolone pharmacophore. 
Appendix: This section reflects all the NMR and IR spectra obtained for all synthesized 
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2.1 Introduction to Antimicrobial Agents 
Antimicrobial drugs have played a critical role in the treatment of infectious diseases and 
have caused major changes in how we treat and halt the propagation of pathogenic 
microorganisms thereby giving us hope in fighting pandemics which have proven to have 
devastating effects upon humanity, however drug resistant microorganisms remain an 
important problem in clinical practice that has proven difficult to solve
1
. If it happens that an 
improper antibiotic happens to be chosen for the treatment of infection with drug-resistant 
microorganisms, the therapy may lead to a worse prognosis. In the case of epidemics, there 
may be quite a limited choice of agents for antimicrobial therapy. Currently fewer new 
antimicrobial agents are being developed and the rate of antimicrobial production is 
devastatingly less than the emergence of drug resistant microorganisms. With this situation in 
mind, we are now facing a situation of severely limited options among antimicrobial agents. 
An antimicrobial agent is an agent that kills microorganisms or inhibits their growth. 
Antimicrobial drugs can be categorized according to the microorganisms they act against. For 
example, antibacterial agents are used against bacteria and antifungal agents are used 
against fungi. They can also be classified according to their function. Agents that kill 
microbes are called microbicidal and those that inhibit their growth are 
called microbiostatic
2
. The main classes of antimicrobial agents are disinfectants 
("nonselective antimicrobials" such as bleach), which kill a wide range of microbes on non-
living surfaces to prevent the spread of illness, antiseptics (which are applied to living tissue 
and help reduce infection during surgery), and antibiotics (which destroy microorganisms 
within the body). The term "antibiotic" originally described only those formulations derived 
from living organisms but is now also applied to synthetic antimicrobials, such as 
the sulphonamides, or fluoroquinolones term also used to be restricted to antibacterials (and 
is often used as a synonym for them by medical professionals and in medical literature), but 




2.2 History of Antimicrobial agents 
Infectious diseases have accounted for a very large proportion of diseases as a whole. It was 
during the 19th century that microorganisms were found to be responsible for a variety of 
infectious diseases that had been plaguing humanity for decades. The first antimicrobial agent 
in the world was salvarsan, an anti-syphilis therapeutic agent which was synthesized by 




Ehrlich in 1910. In 1935, sulphonamides were developed by Domagk and other researchers. 
These drugs were synthetic compounds and had limitations in terms of safety and efficacy. 
Penicillin was discovered in 1928, by Fleming. He found that the growth of Staphylococcus 
aureus was inhibited in a zone surrounding a contaminated blue mold (a fungus from the 
Penicillium genus) in culture dishes, leading to the finding that a microorganism would 
produce substances that could inhibit the growth of other microorganisms. The antibiotic was 
named penicillin, and it came into clinical use in the 1940s. In 1944, streptomycin, an 
aminoglycoside antibiotic, was obtained from the soil bacterium Streptomyces griseus. 
Thereafter, chloramphenicol, tetracycline, macrolide, and glycopeptides (e.g., 
vancomycin) were discovered from soil bacteria. The synthesized antimicrobial agent 










Figure1: Structures of antimicrobial early agents 
 




2.3 Mechanism of action  
Antimicrobial agents take advantage of structural differences between animal cells and 
bacteria (prokaryotes), fungi, or protozoa. The goal is to have highly selective toxicity 
towards these microbes with minimal and preferably no toxicity in humans
5
. Selective 
toxicity is a process whereby the applied antimicrobial agent acts against the parasite but not 
to the host. Selective toxicity could be due to a function of a specific receptor required for 
drug attachment, or it may depend on inhibition of biochemical pathways essential to the 
organism for survival but not to the host. The mechanisms are: (1) Inhibition of cell wall 
synthesis, (2) Inhibition of cell membrane function, (3) Inhibition of protein synthesis, and 
(4) Inhibition of nucleic acid synthesis. 
 
2.4 Classification on mode of Action: 




 Binding of the drug to specific drug receptor PBPs (Penicillin- binding proteins) on 
bacteria. There are 3 to 6 PBPs which have different effects and some are enzymes 
involved in cross-linking reactions. 
 After attachment, peptidoglycan synthesis is inhibited as final transpeptidation is 
blocked followed by inactivation of an inhibitor of autolytic enzyme in the cell wall. 
The autolytic enzymes are activated which lyses the cell and this process results in 
bacterial death. 
 The Gram-positive and Gram-negative bacteria differ in susceptibility to penicillins or 
cephalosporins due to the amount of peptidoglycan, presence of and lipids receptors, 
nature of cross-linking and activity of autolytic enzymes. Gram-positives have a 
thicker peptidoglycan layer than Gram-negative bacteria. 
 
Figure 2: Structures of Penicillin G and cephalosporin C 




2.5 Alteration of cell membrane function.  
Polymyxin, amphotericin B, imidazole are examples
7
. 
 These drugs interfere with the functional integrity of the cytoplasmic membrane. 
Macromolecules and ions escape from the cell causing cell damage or death. 
Structural difference of the cytoplasmic membrane of bacteria and fungi from that of 
animal cells allows for selective toxicity 
 
Figure 3: Structure of polymyxin 
 
2.6 Inhibition of protein synthesis
8
.  
 Bacteria have 70S ribosomes, whereas mammalian cells have 80S ribosomes. 
Subunits of each type of ribosome, their chemical composition, and functional 
specifities differ. Thus a drug can inhibit protein synthesis in bacterial ribosomes but 
not in mammalian ribosomes dure to these structural differences  
  Drugs that act on 50S ribosomal subunit. Chloramphenicol, erythromycin and 
chindamycin are examples. 
 Drugs that act on 30S ribosomal subunit. Tetracycline and aminoglycosides are 
examples. 
 
2.7 Inhibition of nucleic acid synthesis
9-11
.  




 Mechanisms of inhibition include; (a) Inhibition of nucleotide synthesis. 
Sulphonamides, trimethoprin Sulphonamides compete for the enzyme required for 
essential metabolite PABA involved in the synthesis of folic acid needed for synthesis 
of nucleic acid. (b) Inhibition of DNA synthesis. Quinolones block DNA gyrase. (c) 





Figure 4: Structures of Ciprofloxacin and Flucytosine 
 
2.8 Antimicrobial (Drug) Resistance
12-16
 
The capacity of microorganisms to acquire resistance to antimicrobial agents has surpassed 
our imagination. In some cases, antimicrobial agents formerly effective are no longer useful. 
Antibiotic resistance is a form of drug resistance whereby some (or, less commonly, all) 
sub-populations of a microorganism, usually a bacterial species, are able to survive after 
exposure to one or more antibiotics. Pathogens resistant to multiple antibiotics are considered 
multidrug resistant (MDR) or, more colloquially, superbugs. In the simplest cases, drug-
resistant organisms may have acquired resistance to first-line antibiotics, thereby 
necessitating the use of second-line agents. In the case of some MDR pathogens, resistance to 
second- and even third-line antibiotics is, thus, sequentially acquired, a case typically 
illustrated by Staphylococcus aureus in some nosocomial settings. Some pathogens, such 
as Pseudomonas aeruginosa, also possess a high level of intrinsic resistance. 
 
The four main mechanisms by which microorganisms exhibit resistance to antimicrobials are: 
2.8.1 Drug inactivation or modification: for example, enzymatic deactivation 
of penicillin G in some penicillin-resistant bacteria through the production of β-
lactamases. 




2.8.2 Alteration of target site: for example, alteration of PBP—the binding target site 
of penicillins—in MRSA and other penicillin-resistant bacteria 
2.8.3 Alteration of metabolic pathway: for example, some sulfonamide-resistant 
bacteria do not require para-aminobenzoic acid (PABA), an important precursor 
for the synthesis of folic acid and nucleic acids in bacteria inhibited by 
sulfonamides, instead, like mammalian cells, they turn to using preformed folic 
acid. 
2.8.4 Reduced drug accumulation: by decreasing drug permeability or increasing 
active efflux (pumping out) of the drugs across the cell surface 
There are three known mechanisms of fluoroquinolone resistance. Some types 
of efflux pumps can act to decrease intracellular quinolone concentration. In Gram-negative 
bacteria, plasmid-mediated resistance genes produce proteins that can bind to DNA gyrase, 
protecting it from the action of quinolones
17
. Finally, mutations at key sites in DNA gyrase 
or topoisomerase IV can decrease their binding affinity to quinolones, decreasing the drug's 
effectiveness. Research has shown the bacterial protein LexA may play a key role in the 
acquisition of bacterial mutations giving resistance to quinolones and rifampicin. DNA 
damage induces the SOS gene repressor LexA to undergo autoproteolytic activity. This 
includes the transcription of genes encoding Pol II, Pol IV, and Pol V, which are three 








Tuberculosis (TB) is an extremely infectious disease which predominantly affects the lungs 
but it can also affect other organs. It is the world’s second-most fatal infectious agent, 




after HIV/AIDS (WHO, 2013). The bacterium that causes TB, Mycobacterium tuberculosis, 
is transmitted by droplets when an infected person coughs or sneezes. The unique clinical 
characteristics of this dangerous pathogen are a result of its high lipid content. The M. 
tuberculosis complex (MTBC) comprises of four other TB-causing mycobacteria: M. 
bovis, M. africanum, M. canetti, and M. microti. M. africanum is not prevalent in other parts 





In recent years, multi-drug resistant (MDR) tuberculosis as well as extremely drug-resistant 
(XDR) tuberculosis has evolved, threatening the ability to treat this deadly human pathogen. 
Hence, it is of great importance that new drugs and treatment paradigms be made readily 
available to curb this crisis. Historically, one of the most effective therapeutic classes of 
antibacterials have been the structural β-lactam ring class of antibiotics and are widely used 
due to their non-toxicity and safety compared with other agents, all of which contain the 
structural β-lactam ring motif. This class of antibacterial compounds inhibits the bacterial D, 
D-transpeptidases, which catalyze the final step of peptidoglycan cross-linking which is 
essential for cell-wall maturation and cell survival
23-25
.  
Resistance to this class of antibiotics in M. tuberculosis arises from β-lactamase (BlaC), 
which catalyzes the hydrolysis of the β-lactam antibiotic ring
26
. Because of the built-in 
resistance as a result of the production of the β-lactamase, β-lactams have never been 
systematically applied with success to the treatment of TB infections. Accordingly, there is a 
compelling need to develop more effective methods of treatment for tuberculosis, especially 




2.10 Anti-TB drugs  
First Line Treatment for TB comprises of isoniazid in conjunction with pyridoxal 
phosphate to avert peripheral neuropathy caused by isoniazid, rifampicin, pyrazinamide 
and ethambutol for a period of eight weeks followed by the combination treatment with 
isoniazid and rifampicin alone for a further 16 weeks. The patient is considered to be free of 
living bacteria after six months. For latent tuberculosis, the standard treatment regimen is six 
to nine months of isoniazid alone
29-31
. 
















Figure 6: Anti-TB Drugs 
2.11 Second Line Treatment of M.Tuberculosis 
The second line treatment regimen is only used to treat disease that is resistant to first line 
therapy (i.e., for extensively drug-resistant tuberculosis (XDR-TB) or multidrug-resistant 
tuberculosis (MDR-TB))
32
. Some of the drugs used for second line treatment include; 
 aminoglycosides  e.g., amikacin (AMK), kanamycin (KM); 
 polypeptides e.g., capreomycin, viomycin, enviomycin; 
 fluoroquinolones  e.g., ciprofloxacin (CIP), levofloxacin, moxifloxacin (MXF); 
 Thioamides: ethionamide, prothionamide 
 cycloserine 
 terizidone 





Figure 7: Second Line Treatment of M.Tuberculosis 
 
 





Figure 8: Second Line Treatment of M.Tuberculosis  
2.12 Third Line Treatment: 
Third-line drugs include drugs that may be useful, but have uncertain or unproven 
effectiveness. These drugs are listed here either because they are not very effective (e.g., 
clarithromycin) or because their efficacy has not been proven (e.g., linezolid, R207910). 









                                
 
 
Figure 9: Third-line treatment 
2.13 Anti-TB drugs: mechanism of action and resistance 
As an Example, Isoniazid (isonicotinic acid hydrazide, INH) has been the most regularly used 
anti- tuberculosis drug since recognition of its medicinal use in 1952. INH penetrates the host 
cells and diffuses across the M. tuberculosis membrane
35
. INH also requires oxidative 
activation by the M. tuberculosis catalase-peroxidase enzyme KatG and this activation of  
produces oxygen-derived free radicals (superoxide, hydrogen peroxide, and peroxynitrite) 
and organic free radicals that hinder the development of mycolic acids of the bacterial cell 




wall, causing DNA damage and death of the bacillus
36, 37
. The fluoroquinolones currently 
used as second-line drugs in TB treatment exert their potent antibacterial activity by trapping 
DNA gyrase and topoisomerase IV thereby blocking the movement of replication forks and 
transcription complexes. M. tuberculosis however lacks topoisomerase IV, but contains the 
genes gyrA and gyrB encoding the A and B subunits, respectively, of DNA gyrase
33, 38
. 
Resistance to INH consists of KatG mutations, which decrease the drug activity and avert the 
prodrug from being converted into its active metabolite. INH resistance may also arise from 
mutations in the inhA gene, resulting in reduced affinity of the enzyme for NADH without 
affecting its enoyl reductase activity
39
. Mutations in inhA also cause resistance to the 
structurally related second-line drug ethionamide
40
. Fluoroquinolone resistance in M. 
tuberculosis is commonly associated with mutations in the conserved quinolone resistance-






A Research conducted by WHO revealed that 8.2 Million people succumbed to cancer 
globally in 2012 and 60% of the world’s overall new annual cases occur in Africa, Asia and 
central and South America
44
. There are more than 100 types of cancers which can affect any 
part of the body and current drugs as well as measures to halt the propagation and spread of 
cancer in the humans are not effective because of the on-going mutations of existing cancers 
and discovery of new cancers which have devastating effects on the human body
45
. 
Cancer is able to escape the first line of the body’s defence mechanism which is the immune 
system and immunotherapy which involves cancer vaccines, cytokine therapy and 
administration of monoclonal antibodies to block immune checkpoints is not effective to a 
greater extent because of mechanisms such as apoptosis and various mutations that occur and 
continue to propagate cancer throughout the body
46
. 
Cancer is an extremely complex disease which accounts for 10 million new diagnoses world-
wide per annum. Of these, 6.7 million will succumb and at present there are 24.6 million 
cancer patients living with cancer and hoping to survive
47
. Cancer which is also referred to as 
malignant neoplasm or malignancy is a collection of diseases which involves abnormal cell 
growth and it has the ability to invade and spread throughout the body, benign tumours do not 
spread to other parts of the body. No symptoms are observed during early stages of 




development, however symptoms tend to be more visible as the mass continues to grow or 
ulcerates
48
. The findings that result are very much dependant on the location where the cancer 
occurs and the type of cancer. Few cancer symptoms are specific while most of them occur in 
individuals who have other medical conditions.  
Developing countries face an increasing burden of cancer as a result of embracing cancer-
associated lifestyle choices such as ‘‘westernized’’ diets, smoking and physical inactivity. 
According to statistics conducted by GLOBOCAN 2008, there is an annual increase of the 
global burden of cancer and also an increase in the projected number of new cancer cases and 
deaths. This could be as a result of genetic mutations as well as environmental factors
49
.  
The most frequently diagnosed cancer has been found to be breast cancer and it is also the 
prominent cause of death by cancer in females, accounts for 23% of the overall cancer cases 
and 14% of the cancer deaths. In males however, lung cancer has been found to be the 
prominent cause of cancer, comprising 17% of the total new cancer cases and 23% of the 
total cancer deaths. Research in developing countries has shown that the leading cause of 
cancer in females is breast cancer. This is a radical shift from the previous decade where 














2.15 History of Cancer 
The record of history reveals that humans and animals have had the burden of cancer inflicted 
upon them for centuries. The word cancer originated from a Greek word ‘karkinos’ to 
describe carcinoma tumours by a physician Hippocrates (460-370 B.C). Some of the initial 
evidence of cancer was also found amongst fossilized bone tumours, human mummies in 
ancient Egypt, and ancient manuscripts. Growths were also observed in mummies which are 
suggestive of osteosarcoma (bone cancer). The oldest description of cancer was discovered in 
Egypt and goes as far back as 3000 BC
51
. It’s named the Edwin Smith Papyrus and is a copy 
of part of an ancient Egyptian textbook on trauma surgery
52
. It describes 8 cases of tumours 
or ulcers of the breast that were removed by cauterization with a tool called the fire drill. The 
writings describe the disease as untreatable
53
.  
2.16 Causes of Cancer 
Cancer is triggered by the abnormal growth of cells in the body. Cancers tend to be different 
and some types of cancers can be more aggressive than others; however the common 
characteristic is that all cancer cells grow and divide continuously. Others types of cancer 
cells have the ability to metastasize, i.e. they move from a local site to other parts of the body 
through blood circulation or the lymphatic system and they begin to grow and divide, e.g. 
when a lung cancer cell spread to the liver through blood circulation, the cancer is still 
regarded as a lung cancer, not a liver cancer. Generally the development of cancer cells is 
attributed to the damage of DNA in cancer cells, which is not repaired. Damaged DNA can 
be passed from parent to progeny which accounts for inherited cancers. DNA damage occurs 
by different mechanisms and influenced by different factors like smoking, UV-rays, 
carcinogenic chemicals, etc. Apart from inherited genetics the environmental factors play a 
key role in the development of cancer. There are a number of elements that contribute to the 
risk of cancer or cancer death and this includes environmental pollutants, radiation, tobacco, 




Oncoviruses (Cancer causing viruses) are the usual infectious agents that cause cancer. These 
include hepatitis B and C viruses (hepatocellular carcinoma), Kaposi's sarcoma herpes 
virus(Kaposi's sarcoma and primary effusion lymphomas), human papillomavirus(cervical 
carcinoma),Epstein–Barr virus(B-cell lympho-proliferative disease and nasopharyngeal 




carcinoma) and Human T-cell leukaemia virus-1(T-cell leukaemias)
55
. Bacteria and parasites 
also increase the risk of cancer as seen in Helicobacter pylori-induced gastric carcinoma
56
. 
Parasitic infections strongly associated with cancer include Schistosoma haematobium 





Transformation of a normal cell into a cancerous cell requires alteration of (a) Oncogenes – 
these are genes which promote cell growth and reproduction
60
 and (b) Tumour suppressor 
genes – these are genes which inhibit cell division and survival
61
.  
Malignant transformation can occur through the formation of new oncogenes, the over-
expression of normal oncogenes, or by the under-expression and/or disabling of tumour 
suppressor genes. Genetic changes can occur at different levels and by different mechanisms 
such as errors in mitosis can result in the gain or loss of an entire chromosome, mutations, 
which in turn change the nucleotide sequence of genomic DNA while large-scale mutations 
involve the deletion or gain of a portion of a chromosome
62
. Genomic amplification occurs 
when a cell gains many copies (often 20 or more) of a small chromosomal locus, usually 
containing one or more oncogenes and adjacent genetic material. Translocation occurs when 




Mutations also occur in a small scale and these include insertions and deletions as well as 
point mutations which may occur in the promoter region of a gene and affect its expression, 
or may occur in the gene's coding sequence and alter the function or stability of its protein 
product
64
. DNA viruses or retroviruses can disrupt a single gene and this may result from 
integration of genomic material from a virus, leading to the expression of viral oncogenes in 
the affected cell and its progeny
65
. 
Mutations often occur during DNA replication. Even though error correction is built into the 
process and protects the cell against cancer and other replication errors. If substantial amount 
of error occurs the damaged cell will undergo programmed cell death (apoptosis). If the error 




Some of the errors which cause cancer are: 




 A mutation in the error-correcting machinery of a cell might result in rapid accumulation 
of errors and this can be passed from the cell containing the errors to progeny cells
67
. 
 Mutation in an oncogene can result in rapid reproduction of the mutated cell and the 
frequency of reproduction will be greater than its normal counterparts
68
. 
 Loss of a tumour suppressor gene can result due to mutation, disrupting the apoptosis 
signalling pathway and resulting in the cell becoming ‘immortal’
45
. 





Metastasis is the spread of cancer from one part of the body to other locations in the body 
resulting in metastatic tumours. Most cancer deaths are due to cancers that have metastasized. 
Metastasis can occur via the blood circulatory system or the lymphatic system or even both
70
. 
The steps that occur during metastasis are local invasion, intravasation into the blood or 
lymph circulation through the body, extravasation into the new tissue, proliferation 
and angiogenesis. The lungs, liver, brain and the bones are the most common places for 





Figure 11: Schematic illustration of the metastatic process
74
 






2.18 The Cell cycle  
The cell cycle is a sequence of events which take place in a cell prior to replication which 
produces daughter cells. In eukaryotes the cell cycle involves three periods: interphase, the 
mitotic (M) phase and cytokinesis. The three periods consists of different stages and are 
described in table-1. 
 
Table 1: Cell cycle phases and description
75
 
State Description Abbreviation  Description   
Quiescent/ 
Senescent 
Gap O Go A resting phase: The cell has departed from 
the cycle and has stopped further division.  
Interphase Gap 1 G1 The G1 checkpoint control mechanism ensures 
that everything is ready for DNA synthesis. 
Interphase Synthesis S Replication of DNA takes place. 
Interphase Gap 2 G2 G2 is a checkpoint control mechanism which 
ensures that everything is ready to enter 
mitosis. 
Cell division Mitosis M Cell growth is halted at M phase and cellular 
energy is focused on cell division into two 
daughter cells. A Metaphase Check point 
ensures that the cell is ready to undergo 
complete cell division. 
 
2.19 Cancer and the Cell Cycle 
When the cells leave quiescence, they enter the first gap phase (G1) before they enter DNA 
synthesis (S phase). There are many cell signalling pathways that feed into the cell cycle 
machinery in G1. Also in G1 all pre-requisites for proper S-phase progression are being 
checked. A second gap phase (G2) follows before cells enter mitosis (M phase) which is the 
actual cell division phase (Figure 3). The cell cycle is regulated by the activities of protein 
complexes at the molecular level. The core of each complex comprises a cyclin, the essential 
regulatory subunit and a cyclin-dependent kinase (CDK), the catalytic subunit. These 
regulatory units are referred to as checkpoints which are complex signal transduction 
pathways that regulate the order of events in the cell cycle and integrate the cell cycle 




progression with DNA repair
76
. Genetic instability has been shown to emerge as a result of 
the loss of cell cycle checkpoint control
77
. Consequently, the chance that these unstable cells 
will progress to cancer is increased. Improper regulation of cell cycle checkpoint control 
system may lead to independence of growth regulating signals
78
. Abnormal expression of 
positive regulators such as cyclins or the loss of function of negative regulators such as CKIs 











2.20 Cell cycle checkpoints and cancer 
As previously mentioned, the cell cycle proceeds by an ordered set of events where the latter 
events depend upon the integrity and accurate completion of early events in the cell cycle. To 
ensure accuracy of the cell cycle progression, cells are well armed with checkpoints situated 
throughout all phases of the cell cycle. DNA damage activate DNA damage checkpoints that 
arrests cell cycle. DNA damage checkpoints are categorized into at least 3 checkpoints 
according to the cell cycle stages: G1/S (G1) checkpoint, intra-S phase checkpoint, and G2/M 
checkpoint. When DNA replication is activated by drugs that interfere with DNA synthesis, 
DNA lesions, or obstacles on DNA the cells activate DNA replication checkpoint that arrests 
cell cycle at G2/M transition until DNA replication is complete
80
. There are however even 




more checkpoints which play a crucial role in the cell cycle such as the spindle checkpoint, 
which arrests cell cycle at M phase until all chromosomes are aligned on spindle and 
Morphogenesis checkpoint, which plays an important role in the detection of abnormality in 
cytoskeleton and arrests cell cycle at G2/M transition(Figure 4)
81
. Checkpoint failure often 
results in mutations and genomic rearrangements giving rise to genetic instability. In cancer 
cells checkpoints are defective and control mechanisms are usually lost by mutation
82
. Also, 
carcinogenic viruses such as SV40 produce proteins such as T-antigen, which bypass G1/S 
control and transform cells by essentially eliminating p53 and pRb
83
. In addition to cell cycle 
checkpoints, cyclins and CDKs (protein kinases which regulate the cell cycle events such as 
transcription, mRNA processing) provide novel targets for cancer treatment. Chemical 
inhibitors of CDKs include Olomoucine. Recently, a novel peptide was synthesized that 
serves as a docking site for cyclin/CDK2 complexes, inhibiting their action and inducing 
apoptosis preferentially in tumour cells
84
. Chemotherapy which creates multiple cell cycle 
arrests by engaging both the G1/S and the G2/M checkpoints was one of the promising 






















Chemotherapy refers to the treatment of cancer which is mediated by chemical substances, 
particularly one or a combination of anti-cancer drugs. The administration of 
chemotherapeutic agents is always with a therapeutic intent or it may be intended to prolong 
life and reduce symptoms
88
. Chemotherapy is one of the major subdivisions of medical 
oncology along with targeted therapy and hormonal therapy. Most of the time, chemotherapy 
is often used in conjunction with other cancer treatments such as radiation therapy, surgery, 
and/or hyperthermia therapy. Chemotherapeutic agents are cytotoxic therefore also possess 
the ability to damage cells that divide rapidly under normal circumstances such as cells in 
the bone marrow and digestive tract. This results in myelosuppression (decreased production 
of blood cells, hence also immunosuppression), mucositis (inflammation of the lining of the 
digestive tract), and alopecia (hair loss)
89
.Selected new anticancer drugs have been developed 
to be target specific and are not broadly cytotoxic
90
. 
2.21.1 Targeted therapy 
Targeted therapies influence the processes that control division, growth and spread of cancer 
cells as well as the signals that cause cancer cells to die. Targeted therapies interfere with 
specific molecular targets which are associated with cancer and act in various mechanisms 
such as blocking the action of certain enzymes, proteins and other molecules involved in the 
spread of cancer
91
. The actions of targeted therapeutic drugs are often cytostatic, that is they 
block tumour cell proliferation
92
. Other kinds of targeted therapies empower the immune 
system in the killing of cancer cells or they can act on their own to transport toxic substances 
straight to cancer cells and kill them
91
. Examples of targeted therapies include monoclonal 
antibodies as well as small organic molecules. Some of small molecules like trastuzumab, 




2.21.2 Growth signal inhibitors  
Growth signal inhibitors are hormone-like elements that modulate signals responsible for cell 
growth and division. Cetuximab, trastuzumab, imatinib and gefitinibare amongst the first 
targeted therapies that block growth signals
94, 95
.  
2.21.3 Angiogenesis inhibitors  
Angiogenesis refers to the formation of new blood vessels. Agents which inhibit angiogenesis 
are types of targeted therapy which employs drugs or other elements to arrest the formation 
of new blood vessels by tumours
96
. Some angiogenesis inhibitors are endogenous in nature 




and are the part of the body's internal control mechanism. Others 
acquired exogenously through pharmaceutical drugs or even diet. The first angiogenesis 
inhibitor, bevacizumab (Avastin) was approved and discovered in 2004. It is currently used to 
treat advanced colorectal, kidney and lung cancers
97
.   
2.22 Types of drugs used to treat cancer  
2.22.1 Alkylating agents 
These drugs cause damage to DNA to avert the reproduction of cancer and they function 
throughout the phases of the cell cycle. Alkylating agents are used to treat a wide range of 
cancers such as leukemia, Hodgkin disease, multiple myeloma, lymphoma and sarcoma, 
including cancers of the lung, breast, and ovary
98
. 
Since alkylating agents have the potential to cause DNA damage, they can cause long-term 
damage to the bone marrow and in some cases this can ultimately lead to acute leukaemia
99
. 



















 Figure 14: Types of alkylating agents  














Figure 16: Structure of Busalfan 






Figure 17: Triazines 
 








Figure 18: Ethylenimines 
2.22.2 Anti-metabolites 
These drugs hamper DNA and RNA growth and development by replacement of the normal 
building blocks of RNA and DNA. They cause damage to cells during the S phase of the cell 




Anti-metabolites bear a resemblance to either nucleosides or nucleobases however they have 
different chemical groups. These drugs act by either blocking enzymes required for DNA 
synthesis or becoming fused into DNA or RNA. If the enzymes required for DNA synthesis 
are blocked, mitosis is prevented and DNA duplication is halted. Also, after mis-






Figure 19: Antimetabolites 





Figure 20: Antimetabolites 
 
2.22.3 Anti-tumour antibiotics 
Anthracyclines  
These anti-tumour antibiotics cause obstructions in the enzymes which are involved in DNA 
replication and they work in all phases of the cell cycle, however these drugs can cause 









Figure 21: Anthracyclines 
 
Figure 22: Anthracyclines 




2.22.4 Topoisomerase inhibitors 
Topoisomerase inhibitors exert their effect by inhibiting topoisomerase I and II. During DNA 
replication when the DNA double helix is relaxed or transcription, the adjacent unopened 
DNA supercoils. The topoisomerase enzymes come in to play at this point to remove 
torsional stress by producing single or double-strand breaks into DNA and this result in the 
reduction of tension in the DNA strand. This process allows for the normal unwinding of 
DNA to occur during replication or transcription. Inhibition of topoisomerase I or II interferes 
with both of these processes
110
. 
Two of the widely known topoisomerase I inhibitors irinotecan and topotecan are prepared by 
chemical synthesis from the natural product camptothecin, which is acquired from the 
Chinese ornamental tree Camptotheca acuminata
111, 112
.Topoisomerase II inhibitors can be 
categorized into two groups. These inhibitors cause an increased level of enzymes bound to 
DNA and inhibits DNA from replicating and being transcribed. They also encourage DNA 
strand breaks and therefore this can also lead to apoptosis. These Topoisomerase II agents 
include mitoxantrone doxorubicin etoposide and teniposide. The second group are catalytic 
inhibitors and these type of drugs act by hindering the action of topoisomerase II and as a 
result they prevent DNA synthesis and translation
113
. This group of drugs 









Figure 23: Topoisomerase inhibitors 
 




2.23 Examples of Drug targets in cancer 
2.23.1 Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)  
Nuclear factor kappa-light-chain-enhancer of activated B cells(NF-κB)is a transcription 
factor which is important for immunity and inflammation and it is involved in diverse cellular 
responses to stimuli such as bacterial or viral antigens, stress, ultraviolet irradiation, 
cytokines, free radicals, oxidized LDL. The major function of NF-κB is in the regulation of 
the immune response to infection
114
. Research has shown that incorrect regulation of NF-κB 




Activated NF-κB triggers the expression of genes that keep the cell proliferating and protect 
the cell from conditions that induce apoptosis. Abnormalities in NF-κB results in an increased 
susceptibility to apoptosis
117
. This occurs because NF-κB regulates anti-apoptotic genes 
especially theTRAF1andTRAF2 and therefore, checks the activities of the caspase family of 
enzymes, which are central to most apoptotic processes
118
. In tumour cells, NF-κB is active 
either due to mutations in genes encoding the NF-κB transcription factors themselves or in 
genes that control NF-κB activity (such as IκB genes); in addition, some tumour cells secrete 
factors that cause NF-κB to become active. Blocking NF-κB can cause tumour cells to stop 
proliferating to die, or to become more sensitive to the action of anti-tumour agents
119
. Thus, 
NF-κB has become one of the main anti-cancer targets and a subject of choice in cancer 
research. 
Aberrant activation of NF-κB is often detected in several cancers. Furthermore, the 
suppression of NF-κB restricts the multiplication of cancer cells. NF-κB has been noted to be 
a major player in the inflammatory response, hence methods of inhibiting NF-κB signalling 
has potential therapeutic application in cancer and inflammatory diseases
120
. 
Some of reported drugs that inhibit the signalling of NF-κB include metine, fluorosalan, 
sunitinib malate, bithionol, narasin, tribromsalan and lestaurtinib. Their mechanism of action 
of NF-κB signalling inhibition occurs via the inhibition of I-kappa-B-alpha (IκBα) 
phosphorylation
121
. One of the quinolone drugs known to have significant inhibitory activity 
against NF-κB is Moxifloxacin which acts by blocking the activation of NF-κB translocation. 
This drug has also shown to have anti-proliferative and apoptotic effects of Etoposide (VP-









Figure 24: NF-κB inhibitors 
2.23.2 DNA gyrase 
DNA gyrase (a type 2 topoisomerase) is a vital enzyme found in bacteria which catalyses the 
ATP-dependent negative super-coiling of double-stranded DNA
123
. DNA gyrase is a major 
intracellular target for different antibacterial agents. Gyrase is found largely in prokaryotes as 
well as some eukaryotes also posses it, but the enzymes have different affinities for different 
molecules and are immensely different in structure. Humans lack this enzyme; therefore this 
makes gyrase a validated drug target. The two major classes of antibiotics that inhibit gyrase 
are: 
 The quinolones (e.g. nalidixic acid and ciprofloxacin) which act by binding to these 
enzymes and prevent them from de-catenation of DNA that is replicating
124
. 
  Amino-coumarins (e.g. novobiocin)- which work by competitive inhibition of energy 





Figure 25: DNA gyrase inhibitors 
2.23.3 Telomerase 
Telomerase is an enzyme that adds DNA sequence repeats ("TTAGGG" in all vertebrates) to 
the3'end of DNA strands in the telomere regions, which are found at the ends of eukaryotic 
chromosomes
126
. The telomeres region comprises of DNA which is noncoding and also plays 




an important role in the prevention of the loss of important DNA from chromosome ends. 
This result in the loss of only 100–200 nucleotides every time the chromosome is copied and 
this causes no destruction to the organisms DNA. Telomerase is usually expressed in human 
cancer cells and its higher expression produces vulnerability of cancer cells. This increased 
expression renders them distinguishable from normal cells even though normal cells do also 
possess some active telomerase. If telomerase is present abundantly, it permits cells to keep 
growing and dividing. This increased expression of telomerase makes it an attractive target 
for target-based drug design and administration
127-129
 
The activity of telomerase is compulsory for the immortality of many cancers and it is 
inactive in somatic cells. This indicates that inhibition of telomerase can selectively inhibit 
cancer cell progression with minimal side effects
130
. If telomerase is turned off by a drug in 
cancer cells, the telomeres will gradually shorten as these cancer cells carry on dividing and 
ultimately lead to the loss of chromosomes and eventually cell death
131, 132
. Some of the 
newer quinolones such as ofloxacin and levofloxacin have been found to inhibit telomerase 





Figure 26: Telomerase inhibitors 
2.24 Description of quinolones and related analogues 
The quinolone group of antibacterial agents has generated substantial clinical interest since 
their discovery in the early 1960s and they have been widely active against a number of 
bacterial infections
134
. The 4-pyridone-3-carboxylic acid associated with a 5, 6-fused 
aromatic ring is the common chemical feature of bactericidal quinolones
134
. In the resulting 
heterocyclic ring, the 1-, 5-, 6-, 7-, and 8-positions are the main positional targets of chemical 
variation. Many improvements have been made on the basic quinolone ring which includes 
the replacement of hydrogen with fluorine at position 6, substitution with a cyclic amine 
residue at position 7 and addition of new variables at position 1 of the quinolone ring. These 
chemical improvements have led to an improved efficacy of antibacterial activity such as 




improvements of moxifloxacin and garenoxacin
135,136
. The on-going drug resistance 
continues to limit drug choice; however the introduction and application of the new 
quinolones continues to give an exciting overview in antimicrobial chemotherapy. Quinolone 
antibacterial drugs have made a major impact in the field of antimicrobial chemotherapy, 
however they became a neglected group for some years until the development of the 
fluoroquinolones in the 1970s and 1980s
137
. The fluoroquinolones have a broad spectrum of 
activity compared with the earlier compounds. The first generation of quinolones began with 
the introduction of nalidixic acid in 1962 for treatment of urinary tract infections (UTIs)in 
humans
138
. Quinolones achieve their antibacterial effect by preventing bacterial DNA from 
unwinding and duplicating
139
. Most quinolones in clinical use today belong 
to fluoroquinolones, which have a fluorine atom attached to the central ring system, 
characteristically at the 6-position or C-7 position
140, 141
. 
Quinolones are bactericidal and exhibit concentration-dependent killing
142
. The known 
targets where quinolones act are the bacterial DNA gyrase and topoisomerase IV which are 
enzymes essential for DNA duplication and transcription
143
. Newer fluoroquinolones (i.e., 
levofloxacin, sparfloxacin, trovafloxacin and grepafloxacin) are broad-spectrum agents with 
improved biological activity against many Gram-negative and Gram-positive pathogenic 
microorganisms
144, 145
. The quinolone pharmacophore has also been found to inhibit NF-κB 
which is a protein complex that controls transcription of DNA. Incorrect regulation of NF-κB 
has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral 
infection and improper immune development
146-148
. These findings have provided us with a 
firm basis for further research on such compounds to develop more potent derivatives. 
2.25 Natural Sources of Quinolones: Rutaceae Family of Plants  
A Rutaceae family consist of just about 160 genera from which many important compounds 
are synthesized such as limonoids, flavonoids, alkaloids, coumarins and volatile oils
149
. Many 
kinds of alkaloids have also been isolated from these genera which contain aromatic 
heterocyclic rings such as: quinoline and acridine quinazolin. The major part of quinoline 
alkaloids are quinolone derivatives, which are classified into four groups: 2-quinolone, 4-
quinolone, 1-methyl-2-quinolone and 1-methyl-4-quinolone frameworks (Figure-18)
150, 
151
.All quinolone derivatives exhibit medicinal value, among which the 2-quinolone 
derivatives are the focal point in the present thesis. More than 300 quinolone alkaloids 
bearing the 2-quinolone ring have been isolated
152
. Such naturally occurring quinolone 
derivatives have attracted much deserved interest and attention due to their isolations; 




structural elucidation and synthesis have shown to be of major importance with respect to 
combating pathogenic organisms. Some of the reported medicinal properties of 2-quinolones 
derivatives are cytotoxic activity, antitumor activity, antimicrobial activity, antibacterial 





Figure27: Types of quinolones 
2.26 Biological activities of 2 Quinolones 
Most of 2 quinolones derivatives are said to possess a wide range of biological activities 
ranging from antibacterial, anticancer and anti-mycobacterial activities. Moreover, 
substituents at C-7 and C-8 have shown profound biological activity. 
2.26.1 Antimicrobial activity 
Abdel-Ghaniet al., reported the synthesis and antimicrobial activities of new 6-nitro-4-
hydroxy-2-quinolone derivatives. These compounds were evaluated against Gram positive & 
Gram negative bacteria and fungi strains such as Aspergillus nigar and Aspergillus flavus. 










Figure 28: Antimicrobial activity 
2.26.2 Evaluation of novel DNA-gyrase B inhibitors 
Shiroya et al., reported the in silico design, synthesis and evaluation of novel DNA-gyrase B 
inhibitors. Based on docking simulations and results obtained, series of 2-quinolone 
analogues were designed, synthesized, characterized and evaluated for their antibacterial 
activity against S. aureus and E. coli. Compound-2 showed good antibacterial activity against 
S. aureus and E. coli
155. 
 
Figure 29: Antibacterial activity 
2.26.3 Antimalarial activity 
Sarveswari et al., 2014 reported the synthesis and evaluation of 4-hydroxy-2(1H)-quinolone 
derived chalcones, pyrazolines as antimicrobial and antimalarial agents. Among the tested 
compounds 4h and 5d were found to have a potent antimalarial activity than the standard 









Figure 30: Antimalarial activity 
2.26.4 Anticancer activity 
Jayashree et al., reported the synthesis, characterisation, antioxidant and anticancer 
evaluation of novel Schiff bases of 2-quinolones.In vitro cytotoxicity on A549 (lung cancer 
cell line) by MTT assay was employed. The activities of all the test compounds were 
compared to the standard drug Methotrexate, which showed its cytotoxicity at a concentration 
of 1μM. Cytotoxicity was checked at 24 hours duration and compound JMB-7 was found to 




Figure 31: Anticancer activity 
Kumar et al., also reported on the cytotoxic capability of 2-quinolone derivatives using in 
vitro and in vivo (solid tumour and liquid tumour) models of cancer. In vitro cytotoxicity 
studies were carried out in MCF-7 cells by MTT assay and identified potent compounds
158
. 
Figure 32: Anticancer activity 




2.26.5 Anti-inflammatory activity 
Suthar et al., synthesized novel quinolone substituted thiazolidin-4-ones and evaluated as 
anti-inflammatory agents. In vivo anti-inflammatory activity of quinolone substituted 






Figure 33: Anti-inflammatory activity 
 
2.26.6 Antifungal activity 
Heeb et al., reported 4-formyl-1-sulfanyl-2(1H)-quinolone produced by some pseudomonads 





Figure 34: Antifungal activity 
2.27 Justification of the research 
Quinolones are a class of heterocyclic compounds, commonly occurring in nature as 
quinolone alkaloids. Compounds having the 2-quinolone moiety are known to have 
remarkable biological actions including antimalarial, antiviral, and tuberculostatic, 
antibacterial, antifungal, anticancer, antidiabetic, cardiotonic and bronchodilator activity etc. 




Substitution of the 2-quinolone moiety at positions 7 and 8 are critical for potent 
antimicrobial activity. However structural modifications and substitutions at different 
positions of the quinolone ring have also showed potential as anticancer, antimalarial and 





Figure 35: substitutions at various positions of the quinolone ring 
 
Position 1: This position has a hydrophobic interaction with the major grove of DNA. A 
cyclopropyl substituent is now regarded to be the most potent variation here as seen in 
Ciprofloxacin, followed by addition of a 2,4-difluorophenylgroup
164. 
Position 2: This site is very close to the site for DNA gyrase binding so it is believed that any 
added bulky group inhibits access and thus resulting in a lower level of antimicrobial activity. 
Only a sulphur, incorporated into a small ring has been able to replace hydrogen at the R-2 
position
164. 
Positions 3 and 4: These two positions are considered very important for binding to cleaved 
or perturbed DNA, and no useful substitutions have yet been reported. Therefore, the 3-




Position 5: Substitution at this location appear to have the ability to alter overall steric 
configuration of the molecule. reasonably sized additions, such as an amino, hydroxyl, or 
methyl group can noticeably increase in vitro activity against Gram-positive bacteria
166. 
Position 6: Substitution with a fluorine molecule here has shown to improve antimicrobial 
activity compared to the original quinolones, and gave rise to the now widely used and 
clinically successful fluoroquinolones compounds. Whatever structure is placed at this site, 




the substituents at positions 1, 7, and 8 continue to be key determinants of overall biological 
activity in the compounds under active development
167
. 
Position 7: This position directly interacts with DNA gyrase, or topoisomerase IV. The 
optimal substituents are 5- or 6-membered nitrogen heterocycle most commonly, 
aminopyrrolidines and piperazines. Placement of aminopyrrolidine improves Gram-positive 
activity, whereas a piperazine enhances potency against Gram-negative bacteria. Alkylation 
(-CH3) of the 5-membered or 6-membered also enhances activity against Gram-positive 
bacteria. Specific placement of amino or methyl groups on the position 7 has similar 
resultant. Increased bulkiness here has shown to confer protection from the efflux exporter 
proteins of bacteria such as with moxifloxacin and trovafloxacin
168
. 
Position 8: This position has shown to confer overall molecular steric configuration 
Therefore, changes made here affects target affinity, probably by altering drug access to the 
enzyme or DNA binding sites. A free halogen (F or Cl) here may provide improvement in 
activity against anaerobes. Halogen substituents, as well as a methyl or methoxy also increase 
the in vitro activity against Gram-positive cocci. The R-8–substituted quinolones also exhibit 
enhanced bacteriostatic and lethal activities against GyrA mutants of both E. coli and 
Mycobacterium species. Furthermore in S. aureus a substitution here created the most lethal 




Quinolone derivatives have been extensively studied documented for decades and have 
proven to be very effective scaffolds to fight against pathogenic microorganisms Therefore, 
in view of the above facts and in continuation of our search on biologically active hybrid 
molecules, we ideated to synthesize novel quinolone substituted urea and thiourea derivatives 
and their subsequent biological evaluation for anti-cancer, antibacterial and anti-
mycobacterial activity. In this research, the major areas of substitution in the quinolone ring 
are the C-2, C-4 and C-7 positions.  It was considered of interest to synthesize some new 
chemical entities incorporating a methyl group at C-4 and attachment of different 
isocyanates/ and isothiocyanates  to the NH2 group at C-7 at a single molecular frame work 
thus forming a urea and thiourea linkage to investigate their biological activities. 





Figure 36: Proposed 2-quinolone substituted urea model 
2.28 Detailed Research Aims and Objectives 
This research project aims at the design and synthesis of biologically active hybrid molecules 
consisting of 7-amino-4-methyl 2-quinolone pharmacophore coupled with isocynates and 
isothiocynates at C-7 thus forming quinolone-urea hybrid molecule. 
Scheme 1: The synthetic route to prepare 2 quinolone urea/thiourea hybrid compounds 
Detailed objectives 
 To synthesize Novel substituted quinolone derivatives comprising of isocyanates and 
isothiocyanates at C-7 by using conventional Pechman condensation reaction of m-
phenylene diamine with ethylacetoacetate followed by the formation of urea at C-7 by 
refluxing the resulted quinolone with various isocynates and isothiocynates under 
acetonitrile to afford quinolone-phenylurea hybrid compounds.  




CNMR, IR, and LCMS. 
 In vitro antimicrobial activity of the synthesized novel compounds against cancer cell 
lines and a wide range of Gram positive and Gram negative bacteria and 
Mycobacterium tuberculosis (H37Rv).  
2.29 Significance of 2-Quinolones 
2-quinolones are an essential group of compounds which are also isomeric to 4-quinolones 
and isosteric to coumarins
155
. As stated previously, compounds that have the 2-quinolone 
moiety are regarded to possess attention-grabbing biological activities which include 
antimalarial, anticancer, antibacterial, antiviral, cardio-tonic and N-methyl-D-aspartate 




receptor inhibitory functions. Quinolones obstruct the DNA breakage–reunion cycle by 
binding to the subunit A and by blocking the gyrase–DNA complex, whereas the latter act on 
subunit B
170, 171
. The 2-quinolone moiety is positioned in several alkaloids, particularly in the 
Rutaceae family, many of which possess remarkable biologic activity such as 
antihypertensive, cardiotonic, diuretic, anti-inflammatory and bronchodilatory agents
172,161
. 
2.29.1 Examples of the synthesis of 2-quinolones 
A quick and an efficient process for the preparation of a diversely substituted 2-quinolones 
involve the reactions of o-aminoarylketones with an ester containing a reactive α-methylene 
moiety in the presence of a catalytic amount of cerium chloride hepta-hydrate under solvent-




Scheme 2: Preparation of a variety of substituted 2-quinolones 
2.29.2 Reaction with Thiazolidinones 
Sutharet al
159
 reported the reaction of the 7-amino-4-methyl-2-quinolone moiety with 
thiazolidinone which occurs via the formation of a Schiff base to form quinolone substituted 
thiazolidin-4-ones. Synthesized compounds were evaluated for anti-inflammatory and anti-
cancer activities. Compound 6b was found to have potent anti-inflammatory activity and two 
other compounds (1a and 16a) exhibited maximum cytotoxic effect against BT-549, HeLa, 
COLO-205, and ACHN human cancer cell lines. 
 
 
Scheme 3: reaction with thiazolidinones 




2.29.3 Reaction with Schiff bases 
Jayashree et al
157
 reported the synthesis of novel Schiff bases of 2-quinolone as depicted by 
the scheme below. All the synthesized test compounds were screened for their in vitro anti-
proliferative activity against A-549, human lung cancer cell line by MTT assay. The study 
revealed that Schiff’s bases of 2-quinolone ring system can be used for improving the 
chemical status of the existing structures which have shown some anticancer activity. 
 
Scheme 4: Schiff bases of 2-quinolone 
 
      2.29.4 Halogenation Reactions 
Zhao et al
174
 reported the halogenation of the 2-quinolone moiety and prepared 4-substituted-
3-halo-2-quinolones (halo = F, Cl, Br) by utilizing 2-halo diethyl phosphonoacetic acids 
(halo = F, Cl, Br) and o-aminophenyl ketones as the starting materials. The final compounds 
were obtained by an intramolecular Horner–Wadsworth–Emmons olefination of halogen-
containing N-acyl-o-aminophenyl ketones and the transformation process occurred under 
mild conditions. 





Scheme 5: Halogenation of 2-quinolones 
2.29.5 Alkylation of Quinolones 
Chen et al
175
 reported on the reactivity of 8-substituted MeQones. When 1-methyl-3,6, 8-
trinitro-2-quinolone was treated with potassium (or trimethylsilyl) cyanide, cyanation 
proceeded at the 4-position region-selectively as a result of cine-substitution. This reaction is 
initiated with addition of cyanide species, and the cyano-quinolone is formed by the 
protonation of the resultant anionic intermediate followed by elimination of nitrous acid. The 
high reactivity was maintained even when one of the nitro groups on the benzene moiety was 
replaced by a methyl group, which afforded corresponding cine-substituted products upon the 
treatment with potassium cyanide. 
 
Scheme 6: Alkylation of 2-quinolones 
2.29.6 Nucleophilic substitution reactions 
Nishiwakiet al
176
 reported the nucleophilic substitution reaction of 4-chloro-3 nitro-2-
quinolone with various nucleophiles and found the position-4 to be highly active to yield4-




functionalized 3-nitroquinolones. By this method, functional groups such as azide, amino, 
fluoro, alkoxy, alkylthio groups, and malonates are introduced at this position (Table 2).  
 
Scheme 7: Nucleophilic substitution reactions of 2-quinolones 
 
Table 2: Nucleophililes substituted on 2 quinolone ring 
Nucleophilic 
reagent 






F 95 NH3 NH2 91 
MeONa MeO 85 PhCH2NH2 PhCH2NH 94 
PhOH + 
K2CO3 








PhS 96 CH2(COOMe)2 
+ K2CO3 
CH(COOMe)2 95  
 
 
2.29.7 Reaction of quinolones with isocyanates and isothiocyanates 
Haroon et al
177
 reported the synthesis and biological significance of quinolone substituted 
urea and thiourea derivatives. All synthesized compounds displayed activities closer to that of 
enoxacin against all the Gram-positive test strains. The ester intermediate (obtained by acid-
catalysed esterification of enoxacin with methanol was heated under reflux with either 
isocyanates or isothiocyanates at 60
o
Cto afford urea and thiourea derivatives of enoxacin. 





Scheme 8: Reaction of isocynates and isothiocyantes with 2-quinolones 
2.29.8 Synthesis of 7-amino-4-methyl-2-quinolone: 
Since the introduction of nalidixic acid in 1962
178
,extensive work has been carried out on this 
moiety and exploited for its medicinal applications such as antibacterial, anti-tubercular, anti-
inflammatory, anti-cancer agents, however no work has been reported on it with respect to its 
derivatisation with different Isocyanates and Isothiocyanates at C-7 position. Synthesis of 7-
amino-4-methyl-2-quinoloneoccurred through a solvent free Pechman condensation reaction 




Scheme 9: synthesis of 7-amino-4-methyl 2 quinolone 
2.29.9 Synthesis of quinolone-phenyl urea  
Synthesis of quinolone substituted urea derivatives proceeds by an attachment of 
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3.1 General Procedure 





spectroscopic techniques. The analytical grade (AR) chemicals and reagents were obtained 
from Merck and Sigma-Aldrich. The progress of the reactions and the purity of the 
synthesized compounds were monitored by Thin Layer Chromatography on pre-coated silica 
gel 60 F254 (mesh) (E. Merck) and spots were visualized under UV light (long and short 
wavelength). Compounds were purified by recrystallization technique using acetonitrile. 





C NMR spectra were recorded on (Bruker Avance IV) NMR 
spectrometer at 400 and 101 MHz, respectively using DMSO-d6. Perkin Elmer 100 FT-IR 




Scheme 11: Synthetic route for the synthesis of novel series of Quinolone-urea/thiourea 
derivatives 




3.2 Synthesis of 7-amino-4-methyl 2 quinolone 
7-amino-4-methyl-quinoline-2(1H)-one was synthesized by a simple pechman condensation 
reaction which involves the cyclocondensation of m-phenylenediamine and a β-keto ester, 
like ethylacetoacetate. 10.8g (0.1 mol) of m-phenylenediamine and 12.64 ml (0.1 mol) of 
ethylacetoacetate were taken in a 250 ml round bottom flask (RBF). The reaction mixture 
was heated under reflux for 48 hours (as monitored by TLC). After completion of the 
reaction, 200 ml of water was added to the RBF and the contents were heated to the boiling, 
point of water.The mixture was then filtered and the filtrate chilled in the refrigerator till the 
formation of precipitate. The precipitate was collected, dried, washed with hexane and 
recrystallized from ethanol. TLC solvent system: 5% Methanol in DCM. Pure light brown 








3.3 Synthesis of quinolone – phenylurea/phenylthiourea derivatives 
General Procedure:  
Quinolone-urea/thiourea derivatives were prepared by adding the relevant phenyl 
isocyanates/ isothiocyanates(0.2 mol) to the corresponding amino derivative (7-amino-4-
methyl-2-quinolone) (0.1 mol) in acetonitrile and the reaction was refluxed under argon 
atmosphere for 4 hours. After removal of the solvent under reduced pressure,the obtained 









Scheme 10: Synthesis of quinolone-urea/thiourea derivatives 
 
 
Scheme13: Mechanism of the synthesis of 1-(4-methyl-2-oxo-1,2-dihydroquinolin-7-yl)-3-
phenylurea 
 
3.4 Anti-cancer activity (PASS Online) 
Due to human error as well as precipitation and low solubility of the compounds, the MTT 
assay was not successfully conducted. PASS (Prediction of activity spectra for substances) is 
an online prediction tool which predicts over 4000 kinds of biological activity, was used to 
predict the potential activity of the compounds using a template compound
5
. Based on the 




results obtained from the PASS online predictive tool, it was deduced that the compounds 
possess potential anticancer activity; therefore the compounds will be re-evaluated for their 
anticancer activity using an MTT assay. Once troubleshooting is conducted, the MTT assay 
will be carried us as follows; 
Procedure: 
On the first day, 5 ml of complete media will be added to trypsinized cells on a Trypsin one 
T-25 flask. This mixture will be centrifuged in a sterile 15 ml falcon tube at 500 rpm for 5 
min. Media will be removed and the cells were re-suspended to 1.0 ml with complete media. 
The cells will then be counted and recorded per ml. the cells will be diluted (CV=CV) to 
75,000 cells per ml and complete media was used to dilute cells. 100 µl of cells (7500 total 
cells) were added into each well in the 96 well plates and incubated overnight. On the second 
day the cells will be treated with compounds 5a-5k and incubated overnight. The final 
volume was 100 µl per well. On day three 20 µl of 5 mg/ml MTT will added to each well. In 
one set of wells MTT will be added together with the compound but cells will not be added. 
This will served as a control. The 96 well plates will then be incubated for 3.5 h at 37
o
C in 
the culture hood. After the incubation period is over, the media will be carefully removed so 
that cells are not disturbed. 150 µl MTT solvent will be added and the plates covered with 
tinfoil and the cells will then be agitated on an orbital shaker for 15 min. Absorbance will be 
read at 590 nm with a reference filter of 620 nm. The IC50 or the half maximal inhibitory 
concentration will thus be determined. A lower  IC50 value will imply a strong inhibitor the 
and all activities > 100 µM will be considered to be inactive for the cancer cell lines and the 





3.5 In vitro antimicrobial activity 
Encouraging results obtained from cytotoxicity assay prompted the research to further 
evaluate the quinolone-urea/thiourea derivatives for their antimicrobial potential  against 
several bacterial strains (gram negative and gram positive) by known MIC assay 
determination method using resazurin dye
9, 10
. All In vitro antimicrobial activity was 
conducted in collaboration with the Department of Microbiology at Inkosi Albert Luthui 
Hospital in Durban (RSA). 
 




3.5.1 Microorganisms used 
Gram positive microorganism cultures used: Staphylococcus aureus(ATCC 25923), Bacillus 
Subtilis (ATCC 6051). Gram negative microorganism cultures used: Escherichia coli (ATCC 
35218), Pseudomonas aeruginosa(ATCC 27853), Salmonella typhimurium(ATCC), 
Streptococcus pneumonia (ATCC 49619). Fungal strains used: Candida albicans (ATCC 
90028), Cryptococcus neoformans (ATCC 66031). The microorganism culturing and sub-
culturing was performed a day before the commencement of actual testing. 
3.5.2 Preparation of medium  
22 g of Muller-Hinton Broth containing (Acid Hydrolysate of Casein, Beef Extract and 
Starch) was dissolved in 1 L of double distilled water (ddH2O).  The pH of this medium was 
adjusted to 7.4 ± 0.1 and sterilized by autoclave for 15 min at 121°C.  The solution was 
allowed to cool and stored at a temp of 4°C.  Sterility check was performed by incubating un-
inoculated media in an aerobic incubator at 37 °C for 18-24 h. For antifungal activity, RPMI 
1640 medium with L-glutamine and 0.165 M MOPS and without sodium bicarbonate (Lonza) 
was used. 
3.5.3 Preparation of test compounds (stock solution and working standard) 
A quantity of 4.000 mg of the synthesized final compoundsand standard drug (Amoxicillin) 
were dissolved in 1 ml of DMSO to give stock solution (4000 µg/ml).  A further, 100 µl of 
stock solution was diluted with 900 µl of ddH2O to afford working standard solution at a 
concentration of 400 µg/ml. 
3.5.4 Preparation of inoculum 
A colony of microorganisms was suspended in 4.5 ml sterile ddH2O a day before testing 
procedures. Inoculates were adjusted to 0.5 McFarland standard (1.5 X 10
8
cfu/ml) using a 
turbidity-meter.   
3.5.5 Broth micro-dilution method 
In vitro antimicrobial activity of the newly synthesized compounds was evaluated using the 
broth micro-dilution method.  100 µl of sterile ddH2O was added to all outer-perimeter wells 
of a 96-well microtiter plates to minimize evaporation of the medium in the test wells during 
incubation.  To the remaining test wells 100 µl of MHB was added.  Two-fold serial dilutions 








The compounds were tested at final concentration of 200, 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 
0.78, and 0.39 µg/ml. 10 µl of the prepared bacterial or fungal inoculum was added to the 
wells.  The microtiter plates were covered and sealed with parafilm and incubated at 37 ± 1 
ºC for 24 h.  After this, 10 µl of freshly prepared resazurin (0.4 mg/ml) was added to the test 
wells and incubated further for 5h.  MIC was determined as a blue colour in the test well and 
interpreted as no bacterial growth and a pink colour indicated growth. The MIC was thus 
defined at the lowest drug concentration that prevented a colour change from blue to pink.  
This experiment was conducted in duplicate and the average MIC values in µg/ml are 
recorded. 
3.6 Anti-TB activity  
The Anti-TB activity of the synthesized final compounds was also carried out on H37Rv 
strain. This was determined by measuring bacterial growth after 5 d in the presence of test 
compounds. Compounds were prepared as 10-point two-fold serial dilutions in DMSO and 
diluted into 7H9-Tw-OADC medium in 96-well plates with a final DMSO concentration of 
2%. The highest concentration of compound was 200 µM where compounds were soluble in 
DMSO at 10 mM. For compounds with limited solubility, the highest concentration was 50X 
less than the stock concentration e.g. 100 µM for 5 mM DMSO stock, 20 µM for 1 mM 
DMSO stock. For potent compounds, assays were repeated at lower starting concentrations. 
Each plate included assay controls for background (medium/DMSO only, no bacterial cells), 
zero growth (100 µM rifampicin) and maximum growth (DMSO only), as well as a 
rifampicin dose response curve. Plates were inoculated with M. tuberculosis and incubated 
for 5 days: growth was measured by OD590 and fluorescence (Ex 560/Em 590) using a 
BioTek™ Synergy 4 plate reader.  Growth was calculated separately for OD590 and RFU
12-14
. 
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Results and Discussion 





The research project comprised of 11 novel compounds (5a-k) of quinolone substituted urea 
and thiourea derivatives which have been synthesized by means of pechman condensation 
reaction of m-phenylene diamine (1) with ethylacetoacetate (2) to give 7-amino-4-methyl-2-
quinolone (3) followed by nucleophilic attack on the free NH2 group of the quinolone at  C-7 
by isocyanates/isothiocyanates (4) in an inert atmosphere
1
. The reaction of isocyanates and 
isothiocyanates with 7-amino-4-methyl-2-quinolone proceeds without the requirement of a 
catalyst, however in addition to electronic effects, steric hindrances played an important role 
in the reactivity of the NH2 of the quinolone ring therefore the reaction needed up to 4 - 5 
hours to go to completion. 
 








4.1.1 Reaction Mechanisms 
The synthesis of the lead compounds (5a-k) was accomplished through an efficient synthetic 
strategy as outlined in the Scheme-11 and the 7-amino-4-methyl-2-quinolone which served 
as a starting material (3) was synthesized by reacting m-phenylene diamine (1) with 
ethylacetoacetate (2) by a simple condensation reaction without a catalyst. 
 
 
Scheme 12: Mechanism for the synthesis of 7-amino-4methyl-2-quinolone
2
 
Furthermore various isocyanates and isothiocyanates (4) were employed for the synthesis of 
the target compounds (1-(4-methyl-2-oxo-1,2-dihydroquinolin-7-yl)-3-phenylurea or 




Scheme 13: Mechanism of the synthesis of 1-(4-methyl-2-oxo-1,2-dihydroquinolin-7-yl)-3-
phenylurea 




4.1.2 Physicochemical properties 
The synthesized compounds appeared as yellowish, white and slightly cream coloured solids.  
The percentage (%) yield of the synthesized compounds (5a-k) ranged from 50 - 80 %. The 
melting points for the synthesized compounds were found to be between 218 and 370°C 




Table 3: Physio-chemical Properties 
a












Appearance MF MW 
5a H 50 204-206 Yellow 
powder 
C17H15N3OS 309.39 
5b 3-Cl 55 355-357 Yellow 
powder 
C17H14ClN3OS 343.83 
5c 4-Br 50 356-358 White 
powder 
C17H14BrN3O2 372.22 
5d 4-Cl 70 218-220 White 
powder 
C17H14ClN3OS 343.83 
5e 4-OMe 83 370-372 White 
powder 
C18H17N3O3 323.35 
5f 1-Ph 60 227-229 White 
powder 
C21H17N3O2 343.39 
5g 2,4-Cl 45 228-230 White 
powder 
C17H13Cl2N3O2 362.21 
5h 2-Ph 55 368-370 White 
powder 
C18H17N3O2 307.35 
5i 4-F 80 285-287 White 
powder 
C16H12FN3O2 297.29 





48 217-219 White 
powder 
C18H17N3O2 307.35 




4.1.3 Determination of purity 
Purity of the compounds (5a-k) was determined by liquid chromatography (LC) coupled to 
mass spectrometry (MS) with detection by ultraviolet (UV) absorbance and total ion count 
from MS. The percentage purity ranged between 22 and 100% (Table 4) 










4.1.4 Determination of fluorescence 
Fluorescence of compounds (5a-k) was also measured at an excitation wavelength of 560 nm and an 
emission wavelength of 590 nm in a microbiological medium. All compounds displayed no 
fluorescence.  
4.1.5 Spectroscopic Data 





C NMR and EI-MS) which are depicted in the Table 5 and the 
respective spectra for all the compounds were incorporated as appendix. 






5a 22 157.1 293.3 
5b 72 342.1 362.2 
5c 76 113.1 343.4 
5d 68 113.1 323.4 
5e 91 157 343.8 
5f 88 113.1 315.7 
5g 100 113.1 307.4 
5h 90 615.3 311.3 
5i 11 113.1 307.4 
5j 89 420.2 341.8 
5k 75 157 343.8 
    




Table 5.Spectral characterization data of quinolone substituted urea/thiourea derivatives (5a-k)  
Comp
ound 




H NMR [400 MHz, DMSO-d6, δ, ppm] 
13
C NMR [101 MHz, DMSO-
d6, δ, ppm] 
EIMS 
(m/z) 
5a 3081.47 (Ar N-H), 3008.88 (NH of 
urea), 2934.5 (NH of urea), 1641.53 (Ar 
C=O), 1594.52 (C=O of urea), 1553.66 
(Ar CH3) 
 
11.46 (s, 1H, -NH-), 9.04 (s, 1H, -NH-of 
urea) , 8.77 (s, 1H, -NH- of urea), 7.70-7.57 
(m, 4H, Ar-H), 7.23-7.20 (m, 4H, Ar-H), 
6.21 (s, 1H, =CH- of quinolone ring), 2.36 
(s, 3H, -CH3) 
160.9, 151.0, 146.5, 140.3, 
138.5, 137.4, 130.0, 127.4, 
124.2, 117.1, 116.8, 115.9, 






5b 3083.27 (Ar N-H), 3001.94 (NH of 
urea), 2944.31 (NH of urea), 1644.33 
(Ar C=O), 1590.56 (C=O of urea), 
1582.86 (Ar CH3) 
11.54 (s, 1H, -NH-), 10.06 (s, 1H, -NH-of 
thiourea) , 9.92 (s, 1H, -NH- of thiourea), 
7.52-7.49 (m, 4H, Ar-H), 7.36-7.32 (t,J= 
7.74 Hz, 4H, Ar-H), 6.29 (s, 1H, =CH- of 
quinolone ring), 2.38 (s, 3H, -CH3) 
179.3, 161.8, 147.5, 141.2 
139.3, 139.1, 128.4, 124.8, 
124.5, 123.6, 119.3, 117.9, 
117.9, 116.2, 116.1, 1084, 






3131.46 (Ar N-H), 3078.88 (NH of 
urea), 2948.36 (NH of urea), 1644.48 
(Ar C=O), 1604.95 (C=O of urea), 
1584.28 (Ar CH3) 
11.55 (s, 1H, -NH-), 10.15 (s, 1H, -NH-of 
urea) , 9.98 (s, 1H, -NH- of urea), 7.65-7.63 
(d,J=8.68 Hz, 1H, Ar-H), 7.51-7.49 (m, 5H, 
Ar-H), 7.32-7.30 (m, 1H, Ar-H), 6.29 (s, 
1H, =CH- of quinolone ring), 2.38 (s, 3H, -
CH3) 
179.3, 161.8, 147.5, 141.0, 
139.1, 138.7, 131.1, 125.5, 
124.9, 119.4, 117.1, 116.5, 





5d 3130.18 (Ar N-H), 3078.56 (NH of 
urea), 2948.36 (NH of urea), 1644.77 
(Ar C=O), 1516.29 (C=O of 
urea),1398.35 (Ar CH3) 
11.55 (s, 1H, -NH-), 10.14 (s, 1H, -NH-of 
thiourea) , 9.98 (s, 1H, -NH- of thiourea), 
7.65-7.63 (d,J=8.68 Hz, 1H, Ar-H), 7.55-
7.49 (m, 3H, Ar-H), 7.40-7.38 (m, 2H, Ar-
H), 7.33-7.30 (m, 1H, Ar-H), 6.29 (s, 1H, 
=CH- of quinolone ring), 2.38 (s, 3H, -CH3) 
179.4, 161.8, 147.5, 141.0, 
139.1, 138.3, 128.4, 128.2, 
125.3, 124.9, 119.4, 117.1, 





     




5e 3304.99 (Ar N-H), 3006.67 (NH of 
urea), 2898.00(NH of urea), 1695.86 
(Ar C=O), 1636.83 (C=O of urea), 
1607.18 (Ar CH3) 
11.45 (s, 1H, -NH-), 8.92 (s, 1H, -NH-of 
urea) , 8.49 (s, 1H, -NH- of urea), 7.59-7.55 
(m, 2H, Ar-H), 7.37-7.35 (d,J= 8.92 Hz, 2H, 
Ar-H), 7.22-7.19 (m, 1H, Ar-H), 6.88-6.86 
(d,J= 8.92 Hz, 2H, Ar-H), 6.20 (s, 1H, =CH- 
of quinolone ring), 3.71 (s, 3H, Ar-OCH3), 
2.36 (s, 3H, -CH3) 
162.0, 154.6, 152.3, 147.6, 
141.8, 139.6, 132.3, 125.3, 
120.1, 119.8, 118.1, 114.3, 





5f 3275.42 (Ar N-H), 3052.38 (NH of 
urea), 2896.50 (NH of urea), 1696.89 
(Ar C=O), 1656.78 (C=O of urea), 
1637.57 (Ar CH3) 
 
11.52 (s, 1H, -NH-), 9.39 (s, 1H, -NH-of 
urea) , 8.81 (s, 1H, -NH- of urea), 8.13-8.11 
(d,J= 8.32 Hz, 1H, Ar-H), 8.04-8.02 (d,J= 
7.48 Hz, 1H, Ar-H), 8.95-8.93 (d,J= 7.84 
Hz, 1H, Ar-H), 7.67-7.47 (m, 6H, Ar-H), 
7.33-7.30 (d,J= 8.92 Hz, 1H, Ar-H), 7.22-
7.19 (m, 1H, Ar-H), 6.22 (s, 1H, =CH- of 
quinolone ring),2.38 (s, 3H, -CH3) 
162.0, 152.5, 147.6, 141.6, 
139.7, 133.9, 133.6, 128.4, 
125.9, 125.9, 125.8, 125.7, 
125.4, 123.1, 121.2, 118.2, 







5g 3323.26 (Ar N-H), 3282.81 (NH of 
urea), 2988.54 (NH of urea), 1711.83 
(Ar C=O), 1640.22 (C=O of urea), 
1620.48 (Ar CH3) 
11.52 (s, 1H, -NH-), 9.74 (s, 1H, -NH-of 
urea) , 8.44 (s, 1H, -NH- of urea), 8.22-8.20 
(d, J= 8.98 Hz, 1H, Ar-H), 7.63-7.61 (d, J= 
8.58 Hz, 1H, Ar-H), 7.52 (1H, Ar-H), 7.41-
7.38 (d, J= 9.12 Hz 1H, Ar-H),  7.28-7.26 
(m, 1H, Ar-H), 6.23 (s,1H, =CH- of 
quinolone ring), 2.37 (s, 2H, -CH3) 
 
162.0, 151.7, 147.6, 141.1, 
139.6, 134.9, 128.5, 127.6, 
126.3, 125.5, 122.7, 122.0, 







5h 3326.25 (Ar N-H), 3152.37 (NH of 
urea), 2954.46 (NH of urea), 
1696.64 (Ar C=O), 1653.70 (C=O of 
urea), 1632.75 (Ar CH3) 
11.40 (s, 1H, -NH-), 8.91 (s, 1H, -NH-of 
urea) , 7.55-7.52 (d, J= 9.88 Hz, 2H, Ar-H), 
7.35-7.29 (m, 4H, Ar-H), 7.26-7.24 (d, J= 
7.84 Hz, 1H, Ar-H), 7.18-7.15 (d, J= 8.86 
1H, Ar-H), 6.69 (s, 1H, =CH- of quinolone 
ring), 6.17 (s, 1H, -NH- of urea), 4.32-4.30 
(d, J= 5.76 2H, benzylic-H),), 2.34 (s, 3H, -
 
162.0, 154.8, 147.6, 142.3, 
140.1, 139.7, 128.2, 127.1, 
126.7, 125.2, 117.8, 114.0, 











5i 3392.83 (Ar N-H), 3084.77 (NH of 
urea), 2952.07 (NH of urea), 1644.59 
(Ar C=O), 1606.41 (C=O of urea), 
1552.61 (Ar CH3) 
11.56 (s, 1H, -NH-), 10.19 (s, 1H, -NH-of 
urea) , 10.07 (s, 1H, -NH- of urea),  7.66-
7.64 (d, J= 8.68 Hz, 2H, Ar-H), 7.54-7.00 
(m, 3H, Ar-H), 7.35-7.30 (m, 2H, Ar-H), 
7.21-7.16 (m, 1H, Ar-H), 6.30 (s, 1H, =CH- 
of quinolone ring), 2.39 (s, 3H, -CH3) 
179.1, 161.8, 147.6, 141.1, 
139.0, 139.0, 126.2, 126.1, 
124.8, 119.4, 117.2, 116.3, 













5j 3392.83 (Ar N-H), 2958.86 (NH of 
urea), 2917.21(NH of urea), 1692.89 
(Ar C=O), 1643.27 (C=O of urea), 
1626.02 (Ar CH3) 
11.45 (s, 1H, -NH-), 8.95 (s, 1H, -NH-of 
urea) , 8.57 (s, 1H, -NH- of urea),  7.60-7.55 
(m, 2H, Ar-H), 7.35-7.32 (d, J= 8.53 Hz,  
2H, Ar-H),  7.21-7.19 (d, J= 8.68 Hz, 1H, 
Ar-H),  7.10-7.08 (d, J= 8.11  2H, Ar-H), 
6.20 (s, 1H, =CH- of quinolone ring), 2.36 
(s, 3H, -CH3 of quinolone ring), 2.24 (s, 3H, 
-CH3 of benzylic ring) 
162.05, 152.20, 147.68, 
141.69, 139.66, 136.76, 
130.93, 129.18, 125.35, 
118.37, 118.16, 114.45, 






5k 3281.11 (Ar N-H), 3012.55 (NH of 
urea), 2826.97 (NH of urea), 1695.30 
(Ar C=O), 1641.47 (C=O of urea), 
1625.74 (Ar CH3) 
11.47 (s, 1H, -NH-), 9.04 (s, 1H, -NH-of 
urea) , 8.77 (s, 1H, -NH- of urea),  7.70-7.67 
(d, J= 13.23 Hz , 1H, Ar-H), 7.60-7.56 (m, 
 2H, Ar-H), 7.25-7.19 (m, 3H, Ar-
H),), 6.21 (s, 1H, =CH- of quinolone ring), 
2.36 (s, 3H, -CH3 of quinolone ring), 2.26 (s, 
3H, -CH3 of benzylic ring) 
162.0, 152.0, 147.6, 141.4, 
139.6, 138.6, 138.5, 133.0, 
133.0, 131.1, 131.1, 128.4, 
128.3, 125.3, 118.3, 118.2, 










4.1.6 Spectral analysis and elucidation 
4.1.6.1 Infra-red spectroscopy  
Infra-red spectroscopy served as an analytical tool in the identification of different functional 
groups in all the synthesized novel compounds. The characteristic bands of all compounds 
were identified to be the N-H stretches at C-7 of the quinolone ring, the N-H stretches of the 
urea/thiourea which is linked at C-7and the N-H stretches at C-1 of the quinolone ring which 
ranged from 2800.67 – 3334.99. (Quinolone-phenylisothiocyanate) 
 
 
Figure 29: IR spectrum of compound 5e 
 
The IR spectrum of the newly synthesized novel compounds also reflected a consistent 
prominent peak around 1636-1695 cm
-1
which indicated the presence of a carbonyl group 
(C=O) in all the synthesized compounds. Furthermore the IR spectrum reflected peaks around 
1500-1553 cm
-1
which were attributed to the C-C stretch at C4 of the quinolone ring. 
 
 

























Figure 31: IR spectrum of compound 5e 
 
All synthesized compounds showed resemblance of the characteristic peaks in the IR 
spectrum which further confirms the presence of the expected functional groups in the newly 















Figure 32: IR spectrum of compound 5f 
IR of compound 5f also confirmed the formation of the target compounds by displaying 
expected IR peaks at the expected wavelength number. The characteristic peaks were 
observed which confirmed the presence of different functional groups such as NH peaks of 



















H NMR Spectroscopy  
Proton NMR experiment was conducted to confirm the structure of the newly synthesized 
compounds. From the
1
H NMR spectra of the final compounds (5a-k), the characteristic peak 
of the amino group of the quinolone ring (NH) was observed at δ 11.45 ppm. This further 
indicated the integrity or the formation of the quinolone ring. Two distinctive peaks were also 
observed at δ 8.92 and 8.49 ppm and these prominent peaks were attributed to amino (NH) 
protons of the urea linkage as depicted in the figure-34 below. 
 
 







H NMR spectrum of compound 5e 
 
Furthermore, the formation of the 7-amino-4-methylquinolin-2(1H)-one urea/thiourea hybrid 
molecules were evident from the
1
H NMR spectra where the prominent NH peaks resonated at 
δ 11.45ppm , δ 8.92 ppm  and δ 8.49 ppm. These NH peaks confirmed the formation of the 
urea linkage bridge as well as the presence of the quinolone NH. The expected methyl peak 
situated at C-4 of the quinolone ring resonated around δ 2.38 ppm and it was also observed to 
be a singlet peak. C-3 proton of the quinolone ring was observed in the spectrum and signaled 
at δ 6.22 ppm. In addition, the various aromatic protons of the target compounds appeared in 
singlets or either doublets and were observed around δ 8.13-7.30 ppm as shown in the figure-
34. The 
1






























C NMR spectroscopy  
13
C NMR was also used to evaluate and determine the presence of carbon atoms of the 
synthesized compounds. Formation of compounds (5a-k) was confirmed by the appearance 
of a distinctive signal at δ 161.6ppmindicated the presence of the carbonyl group (C=O) at C-
2 of the quinolone ring. Another carbonyl group of the urea linkage resonated at δ 152.3 ppm 
confirmed the integrity of the urea linkage. Another characteristic peak resonated at δ 120.7 
ppm which indicated the presence of the C-H at C-3 of the quinolone ring and also at δ 19.0 
ppm for CH3 group further indicated the formation of the quinolone moiety. The various 
aromatic carbons resonated between δ 147.0 – 113.2 ppm as shown in the figure 37. All of 



































C NMR spectrum of compound 5e 
 
4.2 Anticancer activity (Pass-online prediction) 
PASS (Prediction of activity spectra for substances) is an online prediction tool which 
predicts over 4000 kinds of biological activity, which includes pharmacological effects, 
mechanisms of action, toxic and adverse effects, interaction with metabolic enzymes and 
transporters
1
. PASS has been well accepted by the research community, and actively used in 
the field of medicinal chemistry, by both academic organizations and pharmaceutical 
companies
2
. A model scaffold of the novel compounds was used as a template for predictions 
on the PASS online tool and the results are tabulated in Table 6. The results showed varied 
activities ranging from anti-cancer and anticancer related activities as well as antimicrobial 
and antitubercular activities. 
 
 





Table 6: Pass-online evaluation of synthesized compounds 
 
Number Probability to be 
active (Pa) 
 Probability to be 
inactive (Pi) 
Activity 
1 0.782 0.004 Cytochrome P450 
stimulant 
2 0.525 0.012 Heat shock protein 
antagonist 
3 0.496 0.004 Tyrosine-protein-kinase 
receptor FLT3 inhibitor 
4 0.494 0.047 Leukopoesis stimulant 
5 0.477 0.039 Kinase inhibitor 
6 0.400 0.039 Prostate disorders 
treatment 
7 0.376 0.023 Cancer associated 
disorders treatment 
8 0.368 0.020 Antineoplastic alkaloid 
9 0.353 0.096 Pancreatic elastase 
inhibitor 
10 0.166 0.005 Bacterial efflux pump 
inhibitor 
11 0.285 0.125 Botulin neurotoxin A 
light chain inhibitor 
12 0.175 0.097 Serine-pyruvate 
transaminase inhibitor 
13 0.122 0.044 Interleukin 2 antagonist 
14 0.198 0.122 anticarcinogenic 
15 0.195 0.176 antituberculosic 




4.2.1 Prediction of activity spectra for substances (PASS)  
PASS is freely available online software to predict the potential activity of the novel 
compounds (Ref). Novel quinolone substituted urea/ thiourea were evaluated by PASS and 
the results obtained predicted potential anticancer activity for the synthesized compounds. 
The PASS predicted anticancer activity of the novel compounds were based on their specific 
inhibitory activity against heat shock protein (HSP), Tyrosine-protein-kinase receptor FLT3 
inhibitor, Kinase inhibitor and as antineoplastic alkaloid with probable activity (Pa) values of 
0.525, 0.496, 0.477 and 0.368 respectively. These compounds also displayed low Pi 
(Probable inactive) indexes with all cancer associated hits. Predictions of antitubercular and 
antimicrobial potential of these compounds were low, which was consistent with our 
experimental results.  The probable mechanism of action of the antimicrobial activity of these 
compounds was predicted as efflux pump inhibitors with a Pa index of 0.116 (Table 6).  
The ability of the compound to possess activity could be attributed: 1) Type of scaffold and 
2) Pharmacophoric substituents on the scaffold (electron donating/withdrawing, charge on the 
molecule, hydrophobicity/lipophilicity). The potential activity of the novel compounds 
towards the cancer cell lines was discussed based on the knowledge of the quinolone moiety 
and all pharmacophoric features displayed by the 2-quinolone-urea/thiourea conjugates. All 
hybrids synthesized possessed a wide range of electron donating and electron withdrawing 
groups which have been studied in ring activation
3
. A short virtual screening procedure was 
also conducted using one of the novel compounds as a template on zincpharmer database to 
determine the pharmacophoric features thought to be responsible for activity (Figure 28). 
From the zincpharmer library, 4 compound hits were obtained with similar pharmacophoric 
features. All the results from the virtual screening protocol revealed that these drug 
candidates possessed anticancer activity thus we can also deduce that based on the similarity 
of our novel compounds with those from the virtual screening protocol, we can conclude that 
our compounds could also possess marked activity towards cancer cell lines. The compound 
IDs from the 4 hits from Zincpharmer included Zinc46010622, Zinc46010563, 
Zinc46010602, and Zinc46010582. These compounds contain benzoxazol-urea moieties with 
similar pharmacophoric features with that of our novel 2-quinolone-urea/thiourea derivatives. 
The cytotoxicity results of these benzoxazol compounds ranged from 1.6 µM with MCF-7, 
0.4 µM with PC-3, 0.06 µM with IMR-32 respectively
4
. These results indicate the potential 
of the novel 2-quinolone-urea/thiourea derivatives in its evaluation against cancer cell lines 




based on the comparison of the pharmacophoric features between the virtual screening results 







Figure 28: Pharmacophoric features of 2-quinolone-urea/thiourea 
In vitro anticancer activity 
The novel synthesized compounds were evaluated against a panel of cancer cell lines and our 
preliminary results displayed promising activity. However, these results were not 
reproducible, which could be attributed to human error, precipitation and low solubility of the 
compounds. Based on these factors further troubleshooting was conducted and as a result the 
compounds are being revaluated for their anticancer activity.   
 
4.2.2 In vitro antimicrobial activity 
The quinolone-urea/thiourea derivatives were also evaluated for their antimicrobial potential 
against several bacterial strains (gram negative and gram positive) by known MIC assay 
determination method using resazurin dye
4,5
 (Table 7). This study was conducted to 
determine the activity of the quinolone-urea hybrid compounds on DNA gyrase as well as 
prokaryotic topoisomerases after observing that these kind of compounds could have a 
promising impact on eukaryotic topoisomerases.  
Microorganism used 
Gram positive microorganism cultures used: Staphylococcus aureus (ATCC 25923), Bacillus 
Subtilis (ATCC 6051). Gram negative microorganism cultures used: Escherichia coli (ATCC 
35218), Pseudomonas aeruginosa (ATCC 27853), Salmonella typhimurium (ATCC), 
Streptococcus pneumonia (ATCC 49619). Fungal strains used: Candida albicans (ATCC 
90028), Cryptococcus neoformans (ATCC 66031). The culturing and subculturing of 




microorganism were performed a day before the actual testing and the antimicrobial assay 
was carried out in a collaborative effort at the Department of Microbiology, Inkosi Albert 
Luthuli hospital, Durban, South Africa.  














The MIC values ranged from 12.5 - >200 µg/mL and all compounds exhibited poor to moderate in-vitro activity against the 
screened bacterial strains. The reference drug Amoxicillin indicated an MIC of 0.39 µg/mL. Compound 5f and 5g showed potent 





















5a >200 >200 25 >200 >200 100 
5b >200 >200 25 >200 >200 100 
5c >200 >200 25 >200 100 100 
5d >200 >200 25 >200 >200 100 
5e >200 >200 25 >200 100 50 
5f >200 >200 12.5 >200 >200 100 
5g >200 >200 25 >200 >200 12.5 
5h >200 >200 25 >200 >200 100 
5i >200 >200 25 >200 >200 100 
5j >200 >200 >200 >200 >200 100 
5k >200 >200 >200 >200 >200 25 




4.2.3 Discussion of Antimicrobial Activity 
All the synthesized compounds (5a-5k) were screened for their in vitro antibacterial activity 
against a panel of microorganisms which comprised of three Gram +ve [Staphylococcus 
aureusATCC25923, Bacillus subtilisATCC6051, StrptococcuspneumoniaATCC49691] and 
three Gram –ve [Escherichia coli ATCC35218, Pseudomonas aeruginosaATCC27853, 
Salmonella Typhimurium ATCC].  The MIC results were moderate as seen from compound 
5f and 5g which both had activity of 12.5µg/mL against E.coli and Streptococcus pneumonia. 
Other compounds also showed moderate activity which was around 25µg/mL as seen with 
compounds 5a to 5i for their activity towards E.coli. All compounds showed no activity 
towards other clinical strains (Staphylococcus aureus, Bacillus subtillus, Pseudomonas 
earuginosa, Salmonella typhinium) with activity of >100µg/mL. These results obtained were 
consistent with the PASS online prediction which also predicted very low antibacterial 
activity. 
 Microorganisms have many defense mechanisms at their disposal to combat the action of 
drugs. A probable mechanism which could be responsible for the low activity of our novel 
series of quinolone urea/thiourea hybrid compounds could be the action of efflux pumps
6
. 
Among the various mechanisms involved in bacterial resistance, the balance of membrane 
permeability which controls inflow and outflow of various molecules plays a key role in the 
influx and efflux of antibiotics, thereby limiting their intracellular concentration. Efflux 
pumps have now been shown in both Gram-positive and Gram-negative bacterial pathogens 
as a major resistance strategy
7
. Efflux transporters such as that of E.coli (AcrAB efflux 
system) confers a ‘general resistance mechanism’ that can reinforce the effect of other 
resistance mechanisms such as mutations of the antibiotic targets which will result in the 
inactivity or elimination of the drug
8
. The impact of efflux pumps on antimicrobial resistance 
is also due to the genetic elements which code for these pumps and once these genes mutate 
they are able to survive harsh conditions such as the presence of an antimicrobial agent
9,7
.  
With the above facts in mind, it is hypothesized that the action of the newly synthesized 
hybrid compounds could have been halted by the efflux pumps which could have pumped the 










4.2.4 Invitro characterization of anti-mycobacterial activity 
 The quinolone-urea/thiourea derivatives were further evaluated for their antitubercular 
activity against H37RV strain.  
 
Table 8: Antitubercular activity data (MIC in µM) of a series of novel quinolone 
urea/thiourea derivatives (5a-k) 















4.2.5 Discussion of anti-mycobacterial activity 
The Pass online tool predicted very low levels of activity of these newly synthesized 
compounds towards Tuberculosis with a Pa value of 0.195 and a high Pi value of 0.176. The 
experimental results (MIC >200µM) obtained were in agreement with PASS predicted low 
activity of these compounds towards H37Rv strains.  
A study conducted by Da Silva et al., 2011 showed that tuberculosis confers resistance by a 
different number of mechanisms
11
. Firstly the cell wall of tuberculosis contains complex 
lipids which act as a barrier for drugs to block permeability, secondly tuberculosis consists of 
enzymes which often confers resistance, thirdly tuberculosis consists of drug efflux pumps 
which actively pumps out the drug rendering it ineffective and lastly spontaneous mutations 
within the TB genome gives rise to proteins that make the drug ineffective
12
. With regards to 
this present research the lack of activity of these novel compounds could be due to target 




modification such as mutations in the DNA gyrase and/or topoisomerase IV genes however 
another probable mechanism of resistance which was also thought to hinder the action of 
these compounds to act as antimicrobial agents could be due to the effect of efflux pump 
systems and the inability of the quinolone urea compounds to actively permeate through the 
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The aim of this study was to investigate the effectiveness of eleven newly synthesized 
derivatives of quinolone-urea/thiourea against a panel of cancer cell lines and to further 
evaluate the antitubercular and antimicrobial potential of these derivatives.To a great extent, 
this work has accomplished the aims of the study. Results from this work confirmed the 
following conclusions: 
 The 2-quinolone-urea/thiourea novel compounds are thought to be effective against 
cancer cell lines based on pharmacophoric comparison with a virtual screen derived 
compounds with IC50 values ranging from 0.06 µM to 1.6 µM.  
 The synthesized compounds displayed moderate antimicrobial activities against 
bacterial clinical isolates with MIC values ranging from 12.5 – 50 µg/mL 
 The synthesized compounds however were not able to show any antitubercular 
activity against the H37Rv strain all MIC values of the eleven derivatives were >200 
µM 
 Structural elucidation using spectroscopic techniques such as FT-IR and NMR 
confirmed the formation of the eleven new compounds. 
5.2 Recommendation and Future Studies  
One of the major challenges faced in this research work was synthesizing more compounds 
due the fact that certain isocyanates and isothiocyanates were found to be less reactive to 7-
amino-4-methyl-2-quinolone ring which could be due to steric hindrances and low reactivity 
of the amino group attached at C-7 of the quinolone ring. One of the possibilities which could 
be employed in the formulation of the quinolone-urea/thiourea hybrid compounds can 
involve thereaction ofother plausible positions on the quinolone ring with isocyanates and 
isothiocyanates. Comparative analysis between these quinolone pharmacophore
1,2
 and their 
reactivity towards isocyanates and isothiocyanateswould further provide a deeper insight into 
the mechanisms by which different quinolones react with ureas and thioureas.  
Another approach to gain better anticancer and antibacterial activity of the synthesized 
quinolone derivatives would be solving the solubility concerns of the novel compounds and 
optimization by introducing halogens such as fluorine at a strategic position of the quinolone 
ring. The activity of quinolone-urea/thiourea could also be improved by complexation with 
silver and gold nanoparticles which have been documented by many researchers
3
 and found 
to be effective drug carriers to specific targets and also they confer good electrical 




conductivity on the drugs themselves
4
. This could be a valuable model for optimizing the 
activity of the quinolone-urea/thiourea hybrid molecule.  
Future work would thus include: 
 Enhancement of drug solubility by employing various techniques such as physical 
modifications (Nano-suspension, particle size redusction, co-cyrstalization), chemical 
modifications (Ph change, complexation, salt formation) and other miscellaneous 
methods such as solubilizers, sufactants and novel excipients.  
 Optimization of the quinolone-urea/thiourea by substituting different halogens at 
different positions of the quinolone ring. 
 Employing the activity of nanoparticles as drug carriers during anticancer and 
antimicrobial evaluation. 
 Using synergistic testing possibilities of the synthesized compounds together with 
nanoparticles by disk diffusion assays and checkerboard assay methodologies. 
 Synthesizing a library of 2-quinolone and 4-quinolone compounds and comparing 
their anticancer potential as well as antimicrobial activity when conjugated with 
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Spectrum 33: IR spectrum of compound 5k 
 
